The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...

Jason R. Smith, Pharm.D., appointed as chief pharmacy officer in February 2025 for the University of Rochester Medical Center ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...